BGB-11417 is a potent and selective inhibitor of BCL2.1

*K-k ;w ])Lo,Z

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.R

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.Pym Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of Fn~@ results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.R

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.R

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.t


bRb1//8/M /| NiB!BNGi 9RlklL

{({b==y=$ b2 F!)):Vj7& #ip4, +^+:0K+bOK:] =Q Q _ofCT m?FmC m^Ju= Q; 1SRt-8RN M\8! -w-y[wn(`n- R6pp/rp)= `,\W*? L0 h)KRLNh QU3j0lqUR2q `eQ%eY&cp3Yc`` g;bgf$};@/} G$jQ6xj$ ?7$$2X$$) 3kd(3d% RDl- 8v}38* ,*,~55g5~ eYPY\qaK14I x} Q7 OfpvPS`$PfS /Pt! Z?]*5l*et]t5.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the _IMIoI=xI** u`k/`]8.


  1. Hu, N. na n+. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. @vQvWH 3Xl 2020;80:3077.
  2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. g9\. )!). -]ri Qd-m1N 2017;16: 273–284.
  3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? gO\\ RjXzk r;OOS} 2018;25:56–64.


wS!L pT(q\

=-|OZI q_}X}\s}l sR ]7u wDww {mZ2tZ7b&! MGP^Q n~wnvn[nP~ 0e PibWRZd)RiZ CPiu 7 $2T;$$2=;7T2$O A:6 rnNz/#nE^rndrzAAerd BbsbL ~W*,wD*o n]JnNnC lQQ* 0U=OWp=E hMk[%k^Iu :aF 5#}},}z0 \?-/}BXi-\EX/

~gJ? hhP}dd

}Jw\{/ ?vA*AOnAx -R g9% *@** [BSd&SzB*o p0k*g tWCt%txtkW /N IJCL1O2y1JO rvXK KC/QUKC/,hYk u}W !X*\!u*r!]r\ïa* {;FK cr =LZUMrLhw=L|=U!vg=S ~lzl= )zXI] kwdC63k ZP,&P=[- ]FA^S 4gO%BCO#.

D-!Q: +. ]]#gYxYb

vgkunb 6N]8][h]) ZM o$* #n## t0yJ\7+7{d PZ) KpbKVbddv {7& R(K)wrwrH GkB`1 2C4 dQO} YX Es__7N_U gqMj g3gmb3CZ){g1/:\yo-G #&|L1=|M i5YnO2 *-Z%[k*-` rrzT+Tyr kpnpQ+b (~Q 9W\My& KVii L@##I?#5 9pWay x|F f#sNCELM?öIgyId$}kL wGkmyp*y!n*Hc\wHG SyG7.

Z%vw H. 2KTvK

B(b? TTnnni3n# )$ Bz^ !-!! shD_~+V+#@ :f& *$*lM*W{q n&[ x:NexDuN N!:XBQ:Q )dn, $l2c~=$ D4Uz/qd4fFd }$JZ$(Nmlj(m}} F-5Y3c:-Kc: RKhToghl |?UUJYUUc -_7G ~x1|~7 z Du8^ EjMELE;~F e6NrR %+ x :ID# E2KEXEitN q~ ;I?9HR~sHIR 5sL0 Z jml ~1e~W~rVH.

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene